Author(s):
Leena Varghese, K. Murthi, K. Pandey
Email(s):
leena28492@gmail.com
DOI:
10.5958/0974-360X.2020.00416.3 
Address:
Leena Varghese1, K. Murthi2, K. Pandey3
1KMCH College of Pharmacy, Coimbatore.
2Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER), Hajipur-844102, India.
3Rajendra Memorial Research Institute (RMRI), Patna.
*Corresponding Author
Published In:
Volume - 13,
Issue - 5,
Year - 2020
ABSTRACT:
A study was conducted on a novel dipeptidyl peptidase-4 inhibitor, Teneligliptin when given as an add on therapy with oral anti diabetic agents in patients with type 2 diabetes mellitus. Previously diagnosed subjects with type 2 diabetes (T2DM) were assigned 20 mg/day teneligliptin along with other anti-diabetic drugs. At 3 months, levels of glycemic parameters like HbA1C, fasting blood glucose levels, Post Prandial levels as well as non-glycemic parameters like lipid profile (Total cholesterol, LDL, HDL, Triglycerides), hsCRP level, serum creatinine, Blood urea, BMI were compared with those at baseline. Teneligliptin as an add on therapy led to significant reduction in glycemic parameters like HbA1c (1.6±0.97mg/dl),fasting blood glucose (45.86±62.85), and post prandial levels (72.73±47.97) from the baseline values (p <0.000). Significant co relation was observed between change in HbA1c level and baseline HbA1C levels. Significant reduction in the total cholesterol levels were observed (p < 0.000) but other lipid profile parameters like HDL, LDL, and triglycerides were not shown to be statistically significant after treatment. No change in hsCRP level and BMI was observed. Addition of teneligliptin to oral anti diabetic agents led to a significant improvement in glycemic control in subjects with type 2 diabetes mellitus without causing any weight change.
Cite this article:
Leena Varghese, K. Murthi, K. Pandey. Teneligliptin as an add on Therapy to Oral Anti diabetic agents in type 2 Diabetes Mellitus. Research J. Pharm. and Tech 2020; 13(5): 2310-2314. doi: 10.5958/0974-360X.2020.00416.3
Cite(Electronic):
Leena Varghese, K. Murthi, K. Pandey. Teneligliptin as an add on Therapy to Oral Anti diabetic agents in type 2 Diabetes Mellitus. Research J. Pharm. and Tech 2020; 13(5): 2310-2314. doi: 10.5958/0974-360X.2020.00416.3 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2020-13-5-46
REFERENCES:
1. Mohsen, Hussien and Shaden, H and Faiza, A.Q. and Taghrid, H. (2013). Correlation of serum leptin levels with insulin resistance in Syrian obese patients with type 2 diabetes mellitus. Research Journal of Pharmacy and Technology. 6. 1149-1151.
2. Giugliano D, Maiorino MI, Bellastella G, Esposito K. Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetes-2016. Diabetes Care 2016;39(Suppl. 1):S52-S59. Diabetes Care. 2016;39(6):e86-7.
3. Janardhan S, Sastry GN. Dipeptidyl peptidase IV inhibitors: a new paradigm in type 2 diabetes treatment. Curr Drug Targets. 2014;15(6):600-21.
4. Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P, Swami OC. Teneligliptin in management of type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2016;9:251-60.
5. Sharma HL and Sharma KK, Principles of Pharmacology, 3rd edition, 2017: page 639
6. Thompson AM, Trujillo JM. Advances in the treatment of type 2 diabetes: impact of dulaglutide. Diabetes Metab Syndr Obes. 2016;9:125-36.page;6
7. Amita J et al. Efficacy and safety of voglibose as an add-on triple drug in patients of type two diabetes mellitus uncontrolled with glimepiride and metformin in Punjabi population. Indian Journal of Basic and Applied Medical Research. 2014:3;3:111-116.
8. Shobha Rani G, Lohita M, Jaya Preethi P, Madhavi R, Sunisitha B, Mounika D. Glimepiride: A Review of Analytical Methods. Asian J. Pharm. Ana. 4(4): Oct. - Dec. 2014; Page 178-182
9. Acharya L, Rau N, Udupa N, Rajan M, Vijayanarayana K. Trends in Prescribing Antihypertensive Medications and Lipid Lowering Therapy in type-2 Diabetic Patients in South Indian Tertiary Care Hospital. Research Journal of Pharmacy and Technology. 2016;9(7):857
10. Geetha P, Shanmugasundaram P. A Prospective Observational Study on assessment of risk factor associated with diabetic retinopathy in patients diagnosed with type 2 Diabetes Mellitus in south Indian population. Research Journal of Pharmacy and Technology. 2019;12(2):595
11. Fadheel Q. A Comparative Study of the effect of Metformin and Metformin plus Garlic on Blood Glucose Level in patients with Type 2 Diabetes Mellitus in Iraq. Research Journal of Pharmacy and Technology. 2019;12(4):1806.
12. Mounika V, Sarumathy S, Ebens J, Shanmugarajan T. A prospective study on incidence of Anaemia in type 2 Diabetes Mellitus Patients. Research Journal of Pharmacy and Technology. 2017;10(1):11
13. Raphael M, Vijayanarayana K, Thunga G, Rao N, Sreedharan N. Utilization Pattern of Anti-Diabetic Drugs in Type 2 Diabetes Mellitus in Tertiary Care Hospital. Research Journal of Pharmacy and Technology. 2017;10(7):2063
14. Sindhu L, Kumar B. Effectiveness of Educational Intervention on Body Mass Index (BMI) of Patients with Type 2 Diabetes Mellitus in South Indian Population. Asian Journal of Nursing Education and Research. 2018;8(3):434.
15. Vasudevan N. J., Sara B. A Study to Assess the Effectiveness of Structured Teaching Programme on Knowledge regarding Management of Type 2 Diabetes Mellitus among Patients with Type 2 Diabetes Mellitus attending Diabetic OPD, RMMCH, Annamalai University. Int. J. Nur. Edu. and Research 2(2): April- June 2014; Page 113-116..
16. Kishimoto M. Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2013;6:187-95.
17. Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2012;14(11):1040-6.
18. Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P, Swami OC. Teneligliptin in management of type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2016;9:251-60.
19. 19.Yoshida T, Akahoshi F, Sakashita H, Kitajima H, Nakamura M, Sonda S, et al. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-y lcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem. 2012;20(19):5705-19.
20. Manish Maladkar et al. Teneligliptin: Heralding Change in Type 2 Diabetes, Journal of Diabetes Mellitus. 2016, 6, 113-131.
21. 21.American Diabetes Association ADA 2016 Standards of Medical Care in Diabetes—2016. Diabetes Care. 2016 Jan; VOL 1(Suppl 1): S13
22. Tanaka S, Suzuki K, Aoki C, Niitani M, Kato K, Tomotsune T, et al. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy. Diabetes technology and therapeutics. 2014;16(12):840-5
23. Ghosh S, Trivedi S, Sanyal D, Modi KD, Kharb S. Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study). Diabetes Metab Syndr Obes. 2016;9:347-53
24. Morishita R, Nakagami H. Teneligliptin : expectations for its pleiotropic action. Expert Opin Pharmacother. 2015;16(3):417-26
25. Kutoh E et al. Teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetes. J Clin Med Res. 2014;6(4):287-94
26. Satoh-Asahara N, Sasaki Y, Wada H, Tochiya M, Iguchi A, Nakagawachi R, et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism. 2013;62(3):347-51
27. Tanaka S, Suzuki K, Aoki C, Niitani M, Kato K, Tomotsune T, et al. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy. Diabetes Technology and Therapeutics. 2014;16(12):840-5
28. Foley JE, Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vascular Health and Risk Management. 2010;6:541-8